Shares of Abbott Laboratories were up 0.6% in premarket trading on Friday, the day after the Food and Drug Administration said the company is recalling two laboratory COVID-19 test kits because of concerns about false positives. The tests are the Alinity m SARS-CoV-2 AMP Kits and Alinity m Resp-4-Plex AMP Kits. The FDA previously issued a warning about the potential for false positives with these tests in September. Abbott’s stock is up 7.8% for the year, while the broader S&P 500 has gained 18.1%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
